【摘要】

【摘要】：目的：探索丙戊酸钠联合齐拉西酮或奥氮平对双相情感障碍Ⅰ型患者认知水平、血清尿酸及血脂水平的影响。
方法：本次试验的70例双相情感障碍Ⅰ型患者在2017年2月至2019年2月期间收治，根据单双号随机化分组，各35例，分别采用丙戊酸钠联合奥氮平治疗、丙戊酸钠联合齐拉西酮治疗，并对比两组治疗后4周和8周的蒙特利尔认知量表（MoCA评分）、阳性和阴性症状量表评分（PANSS评分）、躁狂量表（BRMS）评分、血脂、尿酸。
结果：观察组治疗后4周、8周的BRMS评分、PANSS评分低于对照组（P＜0.05），oCA评分高于对照组（P＜0.05），TC、TG、UA优于对照组（P＜0.05）。
结论：对双相情感障碍Ⅰ型患者实施丙戊酸钠联合齐拉西酮治疗效果显著，可改善尿酸、血脂水平，减轻躁狂症状，缓解认知功能障碍。

【Abstract】

【Abstract】Objective: To explore the effect of sodium valproate combined with ziprasidone or olanzapine on the cognitive level, serum uric acid and blood lipid levels of patients with bipolar disorder type I.
Methods: 70 patients with bipolar disorder type I in this trial were admitted between February 2017 and February 2019. They were randomized according to odd and even numbers. 35 patients in each group were treated with sodium valproate combined with olanzapine. Treatment, sodium valproate combined with ziprasidone, and comparing the Montreal Cognitive Scale (MoCA score), positive and negative symptom scale score (PANSS score), and the amount of mania between the two groups at 4 and 8 weeks after treatment Table (BRMS) score, blood lipids, uric acid.
Results: 4 weeks and 8 weeks after treatment, the BRMS score and PANSS score of the observation group were lower than those of the control group (P＜0.05), the oCA score was higher than that of the control group (P＜0.05), and TC, TG and UA were better than the control group (P <0.05).
Conclusion  : Sodium valproate combined with ziprasidone has a significant effect on patients with bipolar disorder type I, which can improve uric acid and blood lipid levels, reduce manic symptoms, and relieve cognitive dysfunction.